Sanofi’s M&A misses frustrate some investors in drugmaker

For the last year, Sanofi’s chief executive has made clear his quest for deals to help revive the fortunes of France’s biggest drugmaker.

The market is still waiting. Olivier Brandicourt’s failure to land two big biotech acquisitions he was chasing has led to growing impatience among some investors.

Read more

Horizon Pharma shareholders approve issuance of ordinary shares in connection with acquisition of Depomed

Dublin-based Horizon Pharma has provided an update on shareholders meeting related to the proposed acquisition of Depomed, Inc., according to which shareholders approved the issuance of up to 81,706,881 ordinary shares of Horizon Pharma plc, in connection with an acquisition of Depomed, Inc.

Read more